课题基金 / 基金详情

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
聚糖和糖缀合物广泛存在于自然界中,在细胞-细胞生物学中起着重要作用。 识别、细胞分化和免疫应答。大多数聚糖和糖基化反应 需要核苷酸糖作为它们的基本组成部分。因此, 核苷酸糖将决定未来基于碳水化合物的创新机会,正如 核苷酸的可用性是今天61亿美元的DNA为基础的PCR市场的先决条件 技术.由于糖科学对核苷酸糖的依赖,迫切需要一种 生产线提供这些必需的试剂。 我们的目标是“化学-酶促合成核苷酸糖库和治疗相关的 快速通道项目是为了满足这一需求,并将一个稳定的,负担得起的和多样化的 供应核苷酸糖,推动糖科学的进步。我们的长期目标是使11 核苷酸糖,26核苷酸衍生物,以及相关的工艺推向市场。在第一阶段目标1中, 我们将酶促合成GDP-L-Fuc、GDP-Man、CMP-Neu 5Ac、CMP-Neu 5Gc和7 UDP 糖:Glc、Gal、GlcNAc、GalNAc、GlcA、GalA和Xyl。在目标2中,我们将创建优化的原位 用于UDP-、GDP-和CMP-糖的生成系统与转移酶反应偶联。我们 这些方法将利用从头或补救途径酶, 反应.在第二阶段目标1中,我们将对核苷酸糖进行化学修饰,形成26种新的衍生物 在CMP-Neu 5Ac上的不同位置含有叠氮基、氟基、脱氧基或甲氧基官能团, GDP-L-Fuc和UDP-GlcNAc/GalNAc。在目标2中,我们将进一步优化所有37个生产平台, 商业化我们的方法将联合收割机化学合成与从头合成和补救途径相结合 酶反应以产生最有效的产物。 该项目的健康相关性与聚糖技术的发展有关, 核苷酸糖作为糖缀合物和多糖的结构单元的基本性质。一 核苷酸糖及其衍生物的稳定供应将促进我们的实验, 了解细胞表面标记、细胞识别和蛋白质-碳水化合物相互作用。反过来, 这种细胞特异性信息有可能影响个体化医疗、药物递送和细胞免疫。 靶向治疗
英文摘要
Glycans and glycoconjugates are widespread in nature and play pivotal roles in cell-cell recognition, cell differentiation, and immunological responses. Most glycans and glycosylation reactions require nucleotide sugars as their essential building blocks. Therefore, the commercial availability of nucleotide sugars will determine future opportunities for carbohydrate-based innovations, just as the availability of nucleotides was a prerequisite for today’s $6.1 billion PCR market of DNA-based technologies. Due to glycoscience’s reliance on nucleotide sugars, there is an urgent need for a production pipeline to provide these essential reagents. The goal of our “Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives” Fast-Track project is to meet this need and commercialize a stable, affordable and diverse supply of nucleotide sugars to drive advances in glycoscience. It is our long-term objective to bring 11 nucleotide sugars, 26 nucleotide derivatives, and the associated processes to market. In Phase I Aim 1, we will enzymatically synthesize GDP-L-Fuc, GDP-Man, CMP-Neu5Ac, CMP-Neu5Gc, and 7 UDP sugars: Glc, Gal, GlcNAc, GalNAc, GlcA, GalA, and Xyl. In Aim 2, we will create optimized in situ generation systems for the UDP-, GDP-, and CMP-sugars to be coupled with transferase reactions. Our methods will utilize de novo or salvage pathway enzymes and be scaled up to 1 gram production reactions. In Phase II Aim 1, we will chemically modify the nucleotide sugars to form 26 new derivatives containing azido, fluoride, deoxy or methoxy functional groups at various positions on CMP-Neu5Ac, GDP-L-Fuc, and UDP-GlcNAc/GalNAc. In Aim 2, we will further optimize all 37 production platforms for commercialization. Our methods will combine chemical synthesis with de novo and salvage pathway enzyme reactions to produce the most efficient products. The health relevance of this project is linked to developments in glycan technology, due the fundamental nature of nucleotide sugars as building blocks for glycoconjugates and polysaccharides. A stable supply of nucleotide sugars and their derivatives will facilitate experiments that advance our understanding of cell surface markers, cell recognition, and protein-carbohydrate interactions. In turn, this cell specific information has the potential to impact individualized medicine, drug-delivery, and cell targeting therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金